Precision immuno-oncology medicine company, Personalis, updated their IPO filing on 6/7/19. The company plans to offer 6,666,667 shares and raise up to $122+ million. Personalis plans to trade on... read more
Precision immuno-oncology medicine company, Personalis, updated their IPO filing on 6/7/19. The company plans to offer 6,666,667 shares and raise up to $122+ million. Personalis plans to trade on... read more
As investor interest in early stage life science companies continues to grow, Third Rock has announced the closing of an oversubscribed fund focused on discovering, launching and building... read more
Clinical-stage biotech, Inhibrx filed the paperwork for its IPO. The company will raise up to $74,750,000 and intends to trade on NASDAQ under the symbol, “INBX.” Inhibrx is based in La Jolla, CA... read more
Seattle based, Adaptive Biotechnologies, has filed for a $230 Million IPO. The company currently offers tools for monitoring several cancer types, sequencing immune system components, and aiding... read more